Evidence map›Paper›PMID 32130756›Full record

ArticleThoracic cancer2020

Health-related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ-5D: A multicenter cross-sectional study.

Youqing Wang, Jufang Shi, Lingbin Du, Huiyao Huang, Le Wang, Juan Zhu, Huizhang Li, Yana Bai, Xianzhen Liao, Ayan Mao and 22 more

Abstract readMulticenter Study
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Modeling the Cost-effectiveness of Esophageal Cancer Screening in China.Cost effectiveness and resource allocation : C/E · 2020
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Youqing WangInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences/Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China.
Jufang ShiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lingbin DuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences/Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China.ORCID 0000-0002-1992-7784
Huiyao HuangOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Le WangInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences/Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China.
Juan ZhuOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Huizhang LiInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences/Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences/Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, China.
Yana BaiInstitute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, China.
Xianzhen LiaoHunan Office for Cancer Control and Research, Hunan Provincial Cancer Hospital, Changsha, China.
Ayan MaoPublic Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, China.
Guoxiang LiuDepartment of Health Economics, School of Health Management, Harbin Medical University, Harbin, China.
Jiansong RenOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaojie SunCenter for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, China.
Jiyong GongScience and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, China.
Qi ZhouChongqing Office for Cancer Control and Research, Chongqing Cancer Hospital, Chongqing, China.
Ling MaiDepartment of Institute of Tumor Research, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Lin ZhuTeaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Xiaojing XingLiaoning Office for Cancer Control and Research, Liaoning Cancer Hospital & Institute, Shenyang, China.
Yuqin LiuCancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, China.
Ying RenUrban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, China.
Bingbing SongHeilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China.
Li LanInstitute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, China.
Jinyi ZhouInstitute of Chronic Non-communicable Diseases Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Peian LouDepartment of Control and Prevention of Chronic Non-Communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou, China.
Xiaohua SunNingbo Clinical Cancer Prevention Guidance Center, Ningbo No.2 Hospital, Ningbo, China.
Xiao QiDepartment of Occupational Medicine, Tangshan People's Hospital, Tangshan, China.
Shouling WuHealth Department of Kailuan Group, Kailuan General Hospital, Tangshan, China.
Wenqiang WeiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kai ZhangOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Min DaiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wanqing ChenOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jie HeOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2018251644Ministry of Science and Technology of the P. R. China; the National Natural Science Foundation of China 81773521National Key Research and Development Program of ChinaNational Key Research and Development Program of China 2016YFC0901405
6 · The paper itself

Abstract

backgroundWe aimed to obtain a set of health state utility scores of patients with esophageal cancer (EC) and precancerous lesions in China, and to explore the influencing factors of health-related quality of life (HRQoL).

methodsA hospital-based multicenter cross-sectional study was conducted. From 2013 to 2014, patients with EC or precancerous lesions were enrolled. HRQoL was assessed using a European quality of life-5 dimension (EQ-5D-3L) instrument. Multivariable linear regression analysis was performed to explore the influencing factors of the EQ-5D utility scores.

resultsA total of 2090 EC patients and 156 precancer patients were included in the study. The dimension of pain/discomfort had the highest rate of self-reported problems, 60.5% in EC and 51.3% in precancer patients. The mean visual analog scale (VAS) score for EC and precancer patients were 68.4 ± 0.7 and 64.5 ± 3.1, respectively. The EQ-5D utility scores for EC and precancer patients were estimated as 0.748 ± 0.009 and 0.852 ± 0.022, and the scores of EC at stage I, stage II, stage III, and stage IV were 0.693 ± 0.031, 0.747 ± 0.014, 0.762 ± 0.015, and 0.750 ± 0.023, respectively. According to the multivariable analyses, the factors of region, occupation, household income in 2012, health care insurance type, pathological type, type of therapy, and time points of the survey were statistically associated with the EQ-5D utility scores of EC patients.

conclusionsThere were remarkable decrements of utility scores among esophageal cancer patients, compared with precancer patients. The specific utility scores of EC would support further cost-utility analysis in populations in China.

Indexed as

Quality of LifeSocioeconomic FactorsAdultAgedCross-Sectional StudiesEsophageal NeoplasmsFemaleFollow-Up StudiesHealth SurveysHumansMaleMiddle AgedPrecancerous ConditionsPrognosisPsychometricsEQ-5D-3Lesophageal cancerhealth-related quality of lifehealth state utilitymultivariable linear regression

Identifiers

PMID32130756
PMCPMC7113059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.